Phase White Matter Signal Abnormalities in Patients with Clinically Isolated Syndrome and Other Neurologic Disorders

J. Hagemeyer, M. Heininen-Brown, T. Gabelic, T. Guttuso Jr, N. Silvestri, D. Lichter, L.E. Fugoso, N. Bergsland, E. Carl, J.J.G. Geurts, B. Weinstock-Guttman, and R. Zivadinov

ABSTRACT

BACKGROUND AND PURPOSE: Identifying MRI biomarkers that can differentiate multiple sclerosis patients from other neurological disorders is a subject of intense research. Our aim was to investigate phase WM signal abnormalities for their presence, prevalence, location, and diagnostic value among patients with clinically isolated syndrome and other neurologic disorders and age-, sex-, and group-matched healthy controls.

MATERIALS AND METHODS: Forty-eight patients with clinically isolated syndrome and 30 patients with other neurologic diseases and a healthy control group ($n = 47$) were included in the study. Subjects were scanned at 3T by using SWI-filtered phase and T2WI, with WM signal abnormalities ≥ 3 mm being classified.

RESULTS: Patients with clinically isolated syndrome had significantly more phase and T2 WM signal abnormalities than healthy controls ($P < .001$). Phase WM signal abnormalities were more prevalent among patients with clinically isolated syndrome compared with patients with other neurologic disorders (4:1 ratio), whereas T2 WM signal abnormalities were more ubiquitous with a 2:1 ratio. The presence of phase WM signal abnormalities was sensitive for clinically isolated syndrome (70.8%) and achieved a moderate-to-high specificity for differentiating patients with clinically isolated syndrome and healthy controls, patients with other neurologic disorders, and patients with other neurologic disorders of other autoimmune origin (specificity, 70%–76.7%). Combining the presence of ≥ 2 phase lesions with the McDonald 2005 and 2010 criteria for dissemination in space improved the specificity (90%), but not the accuracy, in differentiating patients with clinically isolated syndrome from those with other neurologic disorders. In subanalyses among patients with clinically isolated syndrome who converted to clinically definite multiple sclerosis versus those who did not within a 3-year follow-up period, converters had significantly more phase ($P = .008$) but not T2 or T1 WM signal abnormalities.

CONCLUSIONS: Phase WM signal abnormalities are prevalent among patients with clinically isolated syndrome. The presence of (multiple) phase WM signal abnormalities tended to be more predictive of conversion to clinically definite multiple sclerosis and was specific in differentiating patients with clinically isolated syndrome and other neurologic disorders, compared with T2 WM signal abnormalities; however, the accuracy remains similar to that of the current McDonald criteria.

ABBREVIATIONS: CDMS = clinically definite MS; CIS = clinically isolated syndrome; DIS = dissemination in space; HC = healthy control; OND = other neurologic disorders; ROC = receiver operating characteristic; SA = signal abnormality

The occurrence of WM signal abnormalities (SAs) is a hallmark feature of multiple sclerosis, yet the clinical relevance of the pathologic substrate of WM-SAs is disappointing.^{1–4} WM-SAs

observed on T2WI and T1WI represent focal pathology and are thought to be caused by inflammation, edema, demyelination, or gliosis.² They are usually secondary to active inflammation, imaged by using postcontrast T1WI gadolinium-enhanced scanning.⁵ Even though T2 WM-SAs are present at the first demyelinating episode, the poor specificity of conventional MR imaging^{1,6} and comparable MR imaging features at disease onset compared with ischemic, autoimmune diseases or aging limits their predictive value.

Received December 4, 2013; accepted after revision February 24, 2014.

From the Buffalo Neuroimaging Analysis Center (J.H., M.H.-B., T. Gabelic, N.B., E.C., R.Z.) and Baird MS Center (T. Guttuso, N.S., D.L., L.E.F., B.W.-G., R.Z.), Department of Neurology, University at Buffalo, Buffalo, New York; Department of Neurology (T. Gabelic), Referral Centre for Demyelinating Disease of the Central Nervous System, University Hospital Centre Zagreb, Zagreb, Croatia; Istituto Di Ricovero e Cura a Carattere Scientifico (N.B.), Don Gnocchi Foundation, Milan, Italy; and Department of Anatomy and Neurosciences (J.J.G.G.), Section of Clinical Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.

Please address correspondence to Robert Zivadinov, MD, PhD, FAAN, Department of Neurology, School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, 100 High St, Buffalo, NY 14203; e-mail: rzivadinov@bnac.net

Indicates open access to non-subscribers at www.ajnr.org

Indicates article with supplemental on-line tables.

<http://dx.doi.org/10.3174/ajnr.A3969>

Previously, differential diagnosis between MS and other conditions was considered by using brain and spinal cord MR imaging and incorporating number, location, and morphology of T2 WM-SAs in the diagnostic criteria of MS⁷ or by using different nonconventional MR imaging techniques.^{6,8-10} It is important to further investigate the value of nonconventional MR imaging techniques in the MS differential diagnosis, for example by using SWI-filtered phase to identify early focal brain pathology indicative of MS, especially in patients with clinically isolated syndrome (CIS).

Recent studies have confirmed histologically that WM-SAs visible on MR imaging phase and R^{2+} correspond to focal iron deposits, whereas T2 and T1 WM-SAs are influenced by water content.¹¹ A substantial subset of MS WM-SAs has phase shifts^{11,12} and morphologic differences.¹¹⁻¹⁵ However, factors other than nonheme iron may influence the observed WM-SA signal, such as changes in myelin, deoxyhemoglobin, and inflammation.^{11,16-19} Therefore, because there are a multitude of effects, it is not fully known to what extent they each individually influence SWI-filtered phase changes.

Phase changes may signal early WM-SA development^{17,20} in that these phase WM-SAs may appear initially but then disappear as the pathology advances.¹⁷ Considering that the distinct pathologies influencing phase shift (eg, cellular/myelin destruction, iron levels, microstructural changes) in WM-SAs are most likely intricately related and are observed in MS and related disorders,^{12,14,15,21-23} the inquiry into pathology visible on SWI-filtered phase remains important regardless of the causative factors.

SWI-filtered phase work has mostly focused on patients with MS,^{11,13-15,24} high-field-strength imaging,^{11,13,24} or histologically validating phase WM-SAs.^{11,25} Regardless of what pathology phase WM-SAs represent, it is imperative to identify whether their presence has diagnostic value. In the present study, we assessed WM-SAs visible on T2WI and SWI-filtered phase among patients with CIS and patients with other neurologic disorders (OND) to investigate their prevalence, location, and ability to differentiate disease groups.

MATERIALS AND METHODS

Subjects

This study used data from an ongoing prospective study of genetic and environmental risk factors in MS.^{26,27} One-hundred twenty-five subjects satisfied the inclusion criteria: CIS, OND, or healthy control (HC) and having an MR imaging scan obtained with an SWI sequence. Forty-eight patients were diagnosed with CIS (disease duration = 2.8 ± 3.9 years), while 47 HCs were age- and sex-matched to the patients with CIS and OND. From the 48 patients with CIS, subanalyses were performed on 20 patients who underwent a second clinical attack within a 3-year follow-up period (clinically definite multiple sclerosis [CDMS]), 12 remained clinically stable (non-CDMS), while no follow-up was available for 16 patients with CIS. Presented analyses are based on baseline data because the follow-up MR imaging protocols were not standardized. In addition, 30 patients with OND were also included. HCs were recruited from volunteers who had normal neurologic examination findings without a history of any neurologic or psychiatric disorders. Patients with CIS were recruited from the MS

clinic if they had no relapse and were not treated with steroids within the month preceding study entry. The OND group was recruited from the Department of Neurology specialized clinics and consisted of a heterogeneous assortment of neurologic patients that included degenerative ($n = 10$, 33.3%), autoimmune ($n = 10$, 33.3%), and vascular ($n = 10$, 33.3%) disorders. Participants underwent full neurologic assessment and were excluded if they had pre-existing medical conditions or were pregnant. Written informed consent was obtained, and the study protocol was approved by our institutional review board.

MR Imaging Acquisition

Scans were acquired on a 3T Signa Excite HD 12.0 (GE Healthcare, Milwaukee, Wisconsin) by using a multichannel head and neck coil. We acquired the following sequences: 3D flow-compensated gradient-echo for SWI, T2WI and proton attenuation, FLAIR, and T1WI spoiled gradient-echo with magnetization-prepared inversion recovery pulse. Imaging parameters are presented in On-line Table 1.

Image Analysis and White Matter Signal-Abnormality Classification

SWI-filtered phase images were reconstructed, processed, and analyzed as described previously.^{12,15} Each subject's images and WM-SA maps were coregistered into a subject-specific upsampled FLAIR image space ($576 \times 768 \times 64$) with $0.33 \times 0.33 \times 2$ mm voxels. The FMRIB Linear Image Registration Tool software²⁸ (<http://www.fmrib.ox.ac.uk/>) was used to determine the optimal 6 *df* (rigid-body) registration. Images were resampled by using trilinear interpolation, and WM-SA maps were resampled with nearest neighbor interpolation by using the registration matrix of their associated images. Identification of WM-SAs was done by using a semiautomated edge-detection contouring/thresholding technique.²⁹

The classification of phase WM-SAs was previously determined to be reproducible by using the same methodology and rater.¹² Image analyses were performed by a single operator blinded to the clinical status. The operator had 4 years of experience in phase WM-SA identification. WM-SAs were identified separately on T2/proton-attenuation/FLAIR and SWI-filtered phase maps in a blinded manner without a priori knowledge of where the WM-SAs were located with respect to the other technique. Round/oval WM-SAs ≥ 3 mm were included in the study (Fig 1). In addition, a subset of WM-SAs was visible on both SWI-filtered phase and T2/proton-attenuation/FLAIR; these were identified a posteriori as overlapping when ≥ 1 voxel overlapped, after unblinding was performed. Location of both T2 and phase WM-SAs was determined and divided into periventricular, juxtacortical, infratentorial, and deep WM regions according to anatomic location. T2 WM-SAs were classified according to the McDonald 2005³⁰ and 2010⁷ criteria for dissemination in space (DIS).

Global and tissue-specific brain volumes were acquired on 3D T1WI by using SIENAX, Version 2.6, in FMRIB.¹⁵ Normalized volume measures of the whole brain, gray matter, white matter, and lateral ventricles were calculated.

FIG 1. Phase (top) and FLAIR imaging (bottom) WM signal abnormalities in patients with clinically isolated syndrome, other neurologic diseases, and healthy controls. *Red arrows* indicate a hypointense ring on nodular-phase WM-SAs on SWI. Note the presence of phase WM-SA in the right periventricular region in the patient with CIS, which is not present on FLAIR.

Statistical Analysis

Analyses were conducted by using the Statistical Package for the Social Sciences 20.0 (IBM, Armonk, New York) and R for Windows 2.15.2 (R-project; <http://www.r-project.org/>). Demographic characteristics were compared by using the *t* test and χ^2 test. WM-SA characteristics were compared between groups by using the Mann-Whitney *U* test.

Receiver operating characteristic (ROC) analysis curves were computed to calculate the area under the ROC curve for distinguishing CIS, OND, and HC groups on the basis of the frequency of both phase and T2 WM-SAs. To investigate whether the presence of phase-, T2, and overlapping phase T2 WM-SAs can aid in the differential diagnosis of patients with CIS from HCs and patients with OND, we conducted sensitivity, specificity, and accuracy analysis. We also examined whether the use of dichotomized variables (the presence of multiple phase lesions and a combination of multiple phase lesions with fulfillment of the McDonald 2005³⁰ and 2010⁷ criteria for DIS) may further improve sensitivity and specificity in differentiating patients with CIS from those with OND. Analyses were repeated between patients with CIS who remained stable and those who progressed to CDMS after a 3-year follow-up. All *P* values were adjusted by using the false discovery rate at the *P* < .05 level.³¹

RESULTS

Demographic Characteristics

HC subject groups were age- and sex-matched to patients with CIS and OND (Table 1). Patients with CIS and OND had a mean disease duration of 2.8 ± 3.9 years and 12.3 ± 11.2 years, respectively, and patients with CIS had a median Expanded Disability Status Scale score of 1.5 (interquartile range = 1). Patients with CIS had a significantly higher T2 WM-SA volume compared with HCs. Global and tissue-specific brain volumes were consistently smaller in the CIS and OND groups compared with the HC groups but did not reach statistical significance, with the exception of normalized WM volume, which was smaller in patients with CIS. Patients with CIS who converted to CDMS at follow-up did not differ significantly on demographic characteristics from those who did not (*P* > .05).

Presence, Prevalence, and Location of White Matter Signal Abnormalities

Table 2 reports the prevalence of WM-SAs visible on SWI-filtered phase and T2WI and WM-SAs overlapping between these 2 modalities. In total, 186 phase and 770 T2 WM-SAs (92 overlapping) were observed among patients with CIS, whereas HCs only showed 19 phase, 46 T2 WM-SAs, and zero overlapping WM-SAs

Table 1: Demographic characteristics of patients with clinically isolated syndrome and other neurologic disorders and healthy controls^a

	CIS (n = 48)	HC (n = 47)	P	OND ^b (n = 30)	P ^c
Male/female	11:37	12:35	.766	7:23	.827
Age (yr) (mean)	40.7 ± 11.6	40.1 ± 10.7	.814	40.9 ± 15.6	.780
Age at diagnosis (yr) (mean)	38.3 ± 11.6	—	—	34.6 ± 17.1	—
Disease duration (yr) (mean)	2.8 ± 3.9	—	—	12.3 ± 11.2	—
Expanded Disability Status Scale (median ± IQR)	1.5 ± 1	—	—	—	—
Disease modifying therapy (No.) (%)					
No therapy	21, 43.8				
Interferon β 1a	19, 39.6	—	—	—	—
Glatiramer acetate	7, 14.5				
Other	1, 2.1				
Type of OND (No.) (%) ^b					
Degenerative				10 (33.3)	
Autoimmune	—	—	—	10 (33.3)	—
Vascular				10 (33.3)	
WM-SAV	5.1 ± 8.8	0.1 ± 0.3	<.001	3.4 ± 8.6	.042
Normalized brain volume	1532.6 ± 61.9	1556.4 ± 77.9	.103	1549.3 ± 101	.733
Normalized GM volume	785.8 ± 45.7	783.6 ± 45.1	.814	786.9 ± 82.5	.816
Normalized WM volume	746.9 ± 28.9	772.8 ± 49.8	.003	762.4 ± 37.6	.332
Normalized lateral ventricle volume	36.6 ± 15.2	30.5 ± 10.3	.032	36.2 ± 21.9	.151

Note:—CIS indicates clinically isolated syndrome; HC, healthy controls; IQR, interquartile range; OND, other neurological disorders; —, not applicable; WM-SAV, white matter signal abnormality volume.

^a Values are presented as means. Volumetric measurements are presented in milliliters. Groups were compared using the χ^2 test and Student *t* test.

^b Degenerative disease group (n = 10) included patients with Parkinson disease (n = 6), epilepsy (n = 2), cerebellum syndrome (n = 1), and dementia (n = 1); autoimmune disease group (n = 10) included patients with antiphospholipid syndrome (n = 4), systemic lupus erythematosus (n = 3), neurosarcoidosis (n = 1), acute disseminated encephalomyelitis (n = 1), and chronic fatigue syndrome (n = 1); neurovascular disease group (n = 10) included patients with migraine (n = 7), transitory ischemic attack (n = 1), headache (n = 1), and CNS vasculitis (n = 1).

^c P value of OND vs HC.

Table 2: Location of white matter signal abnormalities visible on SWI-filtered phase, T2WI, and their overlaps between patients with clinically isolated syndrome, other neurologic disorders, and healthy controls^a

	CIS (n = 48)			HC (n = 47)			OND (n = 30)			P	P
	(No.) (%)	Mean (SD)	Median	(No.) (%)	Mean (SD)	Median	(No.) (%)	Mean (SD)	Median	CIS vs HC	CIS vs OND
Phase WM-SA											
Total	186 (100)	3.88 (5.18)	2	19 (100)	0.4 (0.85)	0	25 (100)	.83 (2.15)	0	.001	.0001
Periventricular	132 (71)	2.75 (3.26)	2	16 (84.2)	0.34 (0.7)	0	14 (56)	.47 (1.22)	0	.001	.0001
Juxtacortical	15 (8)	0.31 (0.55)	0	0 (0)	0 (0)	0	4 (16)	.13 (.43)	0	.001	.137
Infratentorial	0 (0)	0 (0)	0	0 (0)	0 (0)	0	0 (0)	0 (0)	0	1	1
Deep WM	39 (21)	0.81 (1.99)	0	3 (15.8)	0.06 (0.24)	0	7 (28)	.23 (.68)	0	.012	.232
T2 WM-SA											
Total	770 (100)	16.04 (14.27)	10.5	46 (100)	.98 (2.3)	0	243 (100)	8.1 (11.99)	4.5	.001	.0001
Periventricular	403 (52)	8.4 (5.68)	7.5	4 (9)	.09 (.28)	0	138 (57)	4.60 (4.92)	3	.001	.0001
Juxtacortical	53 (7)	1.10 (1.65)	1	5 (11)	.11 (.43)	0	15 (6)	.50 (1.28)	0	.001	.016
Infratentorial	14 (2)	0.29 (0.68)	0	0	0 (0)	0	1 (0)	.03 (.18)	0	.005	.083
Deep WM	300 (39)	6.25 (8.66)	2.5	37 (80)	.79 (2.1)	0	89 (37)	2.97 (6.63)	0	.001	.010
Overlap											
Total	92 (100)	1.92 (2.97)	1	0 (0)	0 (0)	0	12 (100)	.40 (1.4)	0	.001	.0001
Periventricular	70 (76)	1.46 (2.21)	1	0 (0)	0 (0)	0	5 (42)	.17 (.53)	0	.001	.0001
Juxtacortical	4 (4)	0.08 (0.28)	0	0 (0)	0 (0)	0	3 (25)	.10 (.40)	0	.082	.918
Infratentorial	0 (0)	0 (0)	0	0 (0)	0 (0)	0	0 (0)	0 (0)	0	1	1
Deep WM	18 (20)	0.38 (1.06)	0	0 (0)	0 (0)	0	4 (33)	.13 (.51)	0	.005	.245

^a WM signal abnormality numbers were compared between groups using the Mann-Whitney *U* test. *P* values have been corrected for false discovery rate at the *P* < .05 level.

(all *P* < .001). This yielded a ratio of phase WM-SAs and T2 WM-SAs between CIS and HCs of 10:1 and 16:1, respectively. Most interesting, phase WM-SAs were, on average, more prevalent (4.7:1 ratio) among patients with CIS than among those with OND (CIS mean = 3.88 ± 5.2, OND mean = 0.83 ± 2.15, *P* < .001), whereas T2 WM-SAs were more prevalent at a 2:1 ratio for CIS versus OND (CIS mean = 16.04 ± 14.27 versus OND mean = 8.1 ± 11.99, *P* < .001). In subanalyses among patients with CIS who converted to CDMS versus those who did not within a 3-year follow-up period, converters had significantly more phase (CIS mean = 1.6 ± 1.8 versus CDMS mean = 6.2 ± 6.8, *P* < .01) but not T2 or T1 WM-SAs (*P* > .05).

In ROC curve analysis by using the frequency of phase, T2, and overlapping WM-SAs, the areas under the ROC curve for CIS versus HC were 0.782 (Fig 2A), 0.818, and 0.781, respectively. Phase WM-SAs had a moderate-to-high area under the curve in distinguishing CIS from OND (area under the curve = 0.755, Fig 2B). T2 WM-SAs and overlapping WM-SAs had respective areas under the curve of 0.739 and 0.725.

The most common location of phase WM-SAs across all study groups was the periventricular region (56%–84%), followed by the deep WM (16%–28%) and juxtacortical regions (0%–16%) (Table 2). No phase WM-SAs were observed infratentorially. While phase WM-SAs were relatively confined to the periven-

FIG 2. ROC curves for the number of phase white matter signal abnormalities in differentiating patients with clinically isolated syndrome versus healthy controls (A) and patients with CIS versus those with other neurologic diseases (B).

Table 3: Sensitivity and specificity for the presence of SWI-filtered phase, T2, and their overlapping white matter signal abnormalities among patients with clinically isolated syndrome, other neurologic disorders, and age- and sex-matched healthy controls^a

	CIS vs HC			CIS vs OND		
	Sensitivity	Specificity	Accuracy	Sensitivity	Specificity	Accuracy
Phase WM-SA						
Total	70.8	76.6	73.7 ^b	70.8	76.7	73.1 ^b
Periventricular	66.7	76.6	71.6 ^b	66.7	80	71.8 ^b
Juxtacortical	27.1	100	63.2 ^b	27.1	90	51.3
Infratentorial	0	100	—	0	100	—
Deep WM	27.1	93.8	60 ^c	27.1	86.7	50
T2 WM-SA						
Total	93.9	68.8	81.4 ^b	95.8	13.3	64.1
Periventricular	93.8	91.5	92.6 ^b	93.8	13.3	62.8
Juxtacortical	52.1	93.6	72.6 ^b	52.1	83.3	64.1 ^c
Infratentorial	18.8	100	58.9 ^c	18.8	96.7	48.7
Deep WM	81.3	74.5	77.9 ^b	81.3	53.3	70.5
Overlapping						
Total	55.1	100	77.3 ^b	56.3	90	69.2 ^b
Periventricular	54.2	100	76.8 ^b	54.2	90	67.9 ^b
Juxtacortical	8.3	100	53.7 ^b	8.3	93.3	41
Infratentorial	0	100	—	0	100	—
Deep WM	18.8	100	59 ^c	18.8	93.3	47.4

Note:— indicates not applicable.

^a Sensitivity and specificity were computed using cross-tabulations.

^b $P < .001$.

^c $P < .01$. P values have been corrected for false discovery rate at the $P < .05$ level.

tricular region, the occurrence of T2 WM-SAs was divided between the periventricular and deep WM areas. Of the 19 phase and 46 T2 WM-SAs observed in the HC group, no WM-SAs were visible on both sequences. Ninety-two of the 770 T2 WM-SAs (12%) in patients with CIS were also visible on SWI-filtered phase, while among patients with OND, 12 of the 243 T2 WM-SAs (5%) overlapped the SWI-filtered phase.

Sensitivity and Specificity Analysis

Sensitivity and specificity analysis of phase, T2, and overlapping phase T2 WM-SAs is shown in Table 3. The presence of phase WM-SAs was both a sensitive (70.8%) and specific (76.6%) method of differentiating patients with CIS from HCs. Because of the relatively high prevalence of T2 WM-SAs, the sensitivity was 93.9% but the specificity was lower at 68.8%. A high specificity (100%) but medium sensitivity (55.1%) was observed for WM-SAs visible on both T2 and SWI-filtered phase. Most interesting,

the presence of phase (sensitivity, 70.8%; specificity, 76.7%) and overlapping WM-SAs (sensitivity, 56.3%; specificity, 90%) differentiated relatively well patients with CIS and those with OND ($P < .001$), whereas the presence of T2 WM-SAs yielded high sensitivity (95.8%) but low specificity (13.3%). Additional analyses revealed that patients with OND with autoimmune origin other than CIS (a subset of the OND group, $n = 10$) could be accurately differentiated from patients with CIS when considering the presence of phase (sensitivity, 70.8%; specificity, 70%; accuracy, 70.7%) or overlapping phase T2 (sensitivity, 56.3%; specificity, 80%; accuracy, 60.3%), but not with T2 WM-SAs (sensitivity, 93.9%; specificity, 0%; accuracy, 77.9%).

The presence of ≥ 1 phase WM-SA was more sensitive and similarly specific (Table 3) compared with both the McDonald 2005 (Table 4) and the 2010 (Table 4) criteria for DIS when differentiating patients with CIS and those with OND. When we took into account the presence of multiple phase WM-SAs, the specificity of differentiating patients with CIS from those with OND improved up to 93.3% (Table 4), at the cost of lower sensitivity and accuracy. Combining the presence of multiple phase WM-SAs with the McDonald 2005 and 2010 criteria resulted in high specificity (90%) but lower sensitivity and accuracy.

Similar sensitivity, specificity, and accuracy were calculated between patients with CDMS and non-CDMS when taking into account the combination of McDonald 2005 and 2010 criteria and the presence of multiple phase WM-SAs (On-line Table 2).

DISCUSSION

In this study, the presence, prevalence, and location of phase WM-SAs were investigated in a sample of patients with CIS and OND. There are several important observations from our findings: 1) phase WM-SAs were more prevalent among patients with CIS than in HCs and patients with OND; 2) compared with T2 WM-SAs, phase WM-SAs were specific to patients with CIS and had high overall accuracy compared with individuals with OND and even individuals with OND of autoimmune origin; 3) the presence of > 1 phase WM-SA increased the specificity in differentiating CIS from OND but was similar to the 2005 and 2010 McDonald criteria for DIS by using T2 WM-SAs; 4) the presence of multiple phase WM-SAs was associated with progression to

Table 4: Sensitivity and specificity for the presence of multiple SWI-filtered phase signal abnormalities and fulfillment of the McDonald 2005³⁰ and 2010⁷ criteria for dissemination in space between patients with clinically isolated syndrome and other neurologic disorders^a

	CIS vs. OND		
	Sensitivity	Specificity	Accuracy
≥2 Phase WM-SAs	56.3	83.3	66.7 ^b
≥3 Phase WM-SAs	43.8	90	61.5 ^c
≥4 Phase WM-SAs	43.8	93.3	62.8 ^b
McDonald 2005 criteria for DIS	52.1	80	62.8 ^c
McDonald 2010 criteria for DIS	62.5	76.7	67.9 ^c
≥2 Phase + McDonald 2005 criteria for DIS	33.3	90	55.1
≥2 Phase + McDonald 2010 criteria for DIS	39.6	90	58.9 ^c

Note:—^a $P < .05$. P values have been corrected for false discovery rate at the $P < .05$ level.

^a Sensitivity and specificity were computed using cross-tabulations.

^b $P < .001$.

^c $P < .01$.

CDMS from CIS; 5) approximately half of phase WM-SAs were not detected by T2WI and may represent unique pathology; and 6) the presence of multiple phase WM SAs was associated with higher conversion to CDMS.

To our knowledge, this is the first study quantifying the occurrence of phase WM-SAs in an early disease course suggestive of MS, as well as OND, including those of autoimmune origin. Approximately three-quarters of phase WM-SAs were observed in the periventricular region, regardless of disease type, whereas T2 WM-SAs were commonly observed in both the periventricular and deep WM areas. This observation, coupled with there being no infratentorial phase WM-SAs, suggests that phase WM-SAs are either mostly present near the ventricles or are most readily detected periventricularly. No juxtacortical phase WM-SAs were observed in any of the HC subjects, yet 8% of patients with CIS and 7% of those with OND had phase WM-SAs near the neocortex. This finding suggests that the presence of juxtacortical phase WM-SAs may be specific to CNS disease, though confirmation is needed in a larger, healthy sample. In addition, zero WM-SAs were visible on both SWI-filtered phase and T2WI in the total sample of 47 HCs, making the presence of overlapping phase T2 WM-SAs another potential biomarker for CNS disease. The number of phase WM-SAs was significantly higher in patients with CIS versus HCs, as well as in patients with CIS versus those with OND. Evidently, the amount of phase WM-SAs was the highest among patients with CIS, with a ratio of 10:1 compared with the HC group. Similar results were observed for T2 WM-SAs. Approximately 50% of phase WM-SAs in patients with CIS were not visible on T2WI and might represent different pathology or WM-SAs at different development stages.^{17,32} Inversely, 12% of T2 WM-SAs overlapped with phase WM-SAs, a number in line with but slightly lower than that previously observed (16%–18%) at higher field strengths and in patients at a more advanced disease stage.^{24,33}

Even though this study demonstrates that the presence of phase WM-SAs is both sensitive (70.8%) and specific (76.6%) in distinguishing CIS and HCs, the benefit is not substantial compared with T2 WM-SAs. However, the presence of phase WM-SAs had a high sensitivity and specificity in differentiating patients

with CIS and OND, an observation that was even extended to differentiating patients with CIS from those with OND with autoimmune origin. These 2 findings were specific to phase WM-SAs because the presence of T2 WM-SAs had low specificity, limiting its usefulness. Accuracy, a combined measure of sensitivity and specificity, was also higher for phase WM-SAs. This result can be interpreted as the mere presence of phase WM-SAs being suggestive of CIS, whereas T2 WM-SAs can also be observed in other CNS disorders. Indeed, all subjects with OND of autoimmune origin had at least 1 T2 WM-SA.

A recent study showed marked phase shifts in WM-SAs of patients with MS before they appear on conventional MR imaging.²⁰ Yablonskiy et al¹⁷ reported that the phase contrast observed in MS WM-SAs is dynamic and may be visible at early disease onset. However, others have reported that ringlike phase WM-SAs remained unchanged for several years.¹³ Results from the present study indicate that the specificity in differentiating patients with CIS versus those with OND is increased by the presence of multiple phase WM-SAs, even exceeding the specificity of using McDonald 2005³⁰ and 2010⁷ criteria for DIS. In fact, in subanalyses among patients with CIS who converted to CDMS versus those who did not within a 3-year follow-up, converters had significantly more phase, but not T2 or T1 WM-SAs. These results indicate that phase WM-SA, in addition to T2 WM-SAs, may be a valuable additional tool for diagnosis and conversion to CDMS of early patients with a single demyelinating episode. Compared with the McDonald 2005 and 2010 criteria, the presence of ≥3 phase WM-SAs was more specific in distinguishing CDMS and non-CDMS; and combining the presence of ≥2 phase WM-SAs with the McDonald criteria increased the specificity of identifying CDMS to >90%.

Previously, researchers have investigated other nonconventional MR imaging techniques^{8,9} (eg, magnetization transfer,⁶ diffusion tensor,³⁴ perfusion,¹⁰ and MR spectroscopy³⁵) to potentially increase the level of confidence in the differential diagnosis between MS and other conditions. However, there is no consensus at this time regarding their advantage in the differential diagnosis at first clinical onset. It is currently not entirely understood what phase shifts in WM-SAs constitute. Several properties have been proposed, all of which might have differing levels of effect on phase: iron, demyelination, deoxyhemoglobin, and inflammation, as well as tissue microstructure and fiber orientation.¹¹ In a recent autoimmune encephalomyelitis mouse-model study, phase WM-SAs correlated with all of these factors independently.²⁵ A majority of MS WM-SAs have a central vein as seen on MR venography,^{36,37} and it stands to reason that some WM-SAs visible on SWI-filtered phase are the result of deoxygenated blood in those veins.

The current study included a group of patients with neurologic disorders other than CIS. Drawing conclusions from such a heterogeneous group is challenging. However, the group was included nonetheless to investigate whether there were any contrasting findings compared to patients with CIS. A subset of patients with OND with autoimmune origin confirmed our findings obtained in the whole sample, and even though the sample size was limited, the presence of phase WM-SAs could differentiate this group and patients with CIS, whereas the T2 WM-SAs could

not. Similarly, subanalyses of CDMS versus non-CDMS were also conducted on a limited sample size. Another limitation of the present study is that subtypes of phase WM-SAs based on their appearance were not investigated.^{12–14} Furthermore, the subjects with CIS in the present study were not imaged at clinical onset and may, therefore, represent slightly more advanced patients, potentially influencing the findings. Longitudinal studies are needed to evaluate the value of phase lesions in diagnosing and monitoring patients with CIS and CDMS by dissemination in time and the potential effect of disease-modifying therapy.

CONCLUSIONS

This study showed that WM-SAs visible on SWI-filtered phase are relatively specific to patients with CIS, even compared with individuals with OND of autoimmune origin. This finding could render the imaging of phase WM-SAs a potential biomarker aiding in the differential diagnosis. Future longitudinal studies should reveal the source of phase contrast (iron, demyelination, deoxyhemoglobin, inflammation, and so forth) and thoroughly investigate its clinical significance in CNS disorders.

Disclosures: Thomas Guttuso Jr—**UNRELATED**: Received personal compensation from Teva Pharmaceuticals for speaking and consulting services and from Duchesnay, Inc for consulting services. Nicholas Silvestri—**UNRELATED**: Received personal compensation for consulting from Biogen Idec. David Lichter—**UNRELATED**: Received personal compensation for speaking from Teva Neuroscience and UCB Pharma. Jeroen J.G. Geurts—**UNRELATED**: Has served as a consultant for Merck Serono, Biogen Idec, Teva Pharmaceuticals, Genzyme, and Novartis; received personal compensation for speaking from Novartis, Teva, and Merck Serono and research support from Biogen, the Dutch MS Research Foundation, Merck Serono, and Multiple Sclerosis Society of Canada. Bianca Weinstock-Guttman—**UNRELATED**: Received honoraria for serving in advisory boards and educational programs from Teva Pharmaceuticals, Biogen Idec, Novartis, Accordia, EMD Serono, and Genzyme. She received speaker honoraria from Biogen Idec, Teva Neuroscience, EMD Serono, Novartis, Pfizer, Genzyme, and Accordia. She also received support for research activities from the National Institutes of Health, National Multiple Sclerosis Society, National Science Foundation, Department of Defense, EMD Serono, Biogen Idec, Teva Neuroscience, Cyberonics, Novartis, Accordia, Pfizer, Genzyme, and the Jog for the Jake Foundation. Robert Zivadinov—**UNRELATED**: Received consulting fees from Teva Pharmaceuticals, Biogen Idec, Genzyme-Sanofi, Novartis, Claret, and EMD Serono and speaker honoraria from Teva Pharmaceuticals, Biogen Idec, Genzyme-Sanofi, Novartis, and EMD Serono. He has received research support from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme-Sanofi, Novartis, and Claret.

REFERENCES

- Poloni G, Minagar A, Haacke EM, et al. **Recent developments in imaging of multiple sclerosis.** *Neurologist* 2011;17:185–204
- Filippi M, Rocca MA, De Stefano N, et al. **Magnetic resonance techniques in multiple sclerosis: the present and the future.** *Arch Neurol* 2011;68:1514–20
- Barkhof F. **The clinico-radiological paradox in multiple sclerosis revisited.** *Curr Opin Neurol* 2002;15:239–45
- Barkhof F. **MRI in multiple sclerosis: correlation with Expanded Disability Status Scale (EDSS).** *Mult Scler* 1999;5:283–86
- Miller DH, Barkhof F, Nauta JJ. **Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis.** *Brain* 1993;116(pt 5):1077–94
- Rovaris M, Holtmannspotter M, Rocca MA, et al. **Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study.** *Mult Scler* 2002;8:52–58
- Polman CH, Reingold SC, Banwell B, et al. **Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.** *Ann Neurol* 2011;69:292–302
- Govoni M, Castellino G, Padovan M, et al. **Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus.** *Lupus* 2004;13:149–58
- Triulzi F, Scotti G. **Differential diagnosis of multiple sclerosis: contribution of magnetic resonance techniques.** *J Neurol Neurosurg Psychiatry* 1998;64(suppl 1):S6–14
- Zivadinov R, Bergsland N, Stosic M, et al. **Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis.** *Neurol Res* 2008;30:816–26
- Yao B, Bagnato F, Matsuura E, et al. **Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging.** *Radiology* 2012;262:206–15
- Hagemeyer J, Heininen-Brown M, Poloni GU, et al. **Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study.** *J Magn Reson Imaging* 2012;36:73–83
- Bian W, Harter K, Hammond-Rosenbluth KE, et al. **A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis.** *Mult Scler* 2013;19:69–75
- Haacke EM, Makki M, Ge Y, et al. **Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging.** *J Magn Reson Imaging* 2009;29:537–44
- Zivadinov R, Heininen-Brown M, Schirda CV, et al. **Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study.** *Neuroimage* 2012;59:331–39
- Langkammer C, Krebs N, Goessler W, et al. **Susceptibility induced gray-white matter MRI contrast in the human brain.** *Neuroimage* 2012;59:1413–19
- Yablonskiy DA, Luo J, Sukstanskii AL, et al. **Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis.** *Proc Natl Acad Sci U S A* 2012;109:14212–17
- Schweser F, Deistung A, Lehr BW, et al. **Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism?** *Neuroimage* 2011;54:2789–807
- Hagemeyer J, Geurts JJ, Zivadinov R. **Brain iron accumulation in aging and neurodegenerative disorders.** *Expert Rev Neurother* 2012;12:1467–80
- Wiggermann V, Hernandez Torres E, Vavasour IM, et al. **Magnetic resonance frequency shifts during acute MS lesion formation.** *Neurology* 2013;81:211–18
- Craels W, Migdal MW, Luessenhop CP, et al. **Iron deposits surrounding multiple sclerosis plaques.** *Arch Pathol Lab Med* 1982;106:397–99
- Ferguson B, Matyszak MK, Esiri MM, et al. **Axonal damage in acute multiple sclerosis lesions.** *Brain* 1997;120(pt 3):393–99
- Trapp BD, Ransohoff R, Rudick R. **Axonal pathology in multiple sclerosis: relationship to neurologic disability.** *Curr Opin Neurol* 1999;12:295–302
- Grabner G, Dal-Bianco A, Scherthaner M, et al. **Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI.** *J Magn Reson Imaging* 2011;33:543–49
- Nathoo N, Agrawal S, Wu Y, et al. **Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination.** *Mult Scler* 2013;19:721–31
- O'Connor K, Weinstock-Guttman B, Carl E, et al. **Patterns of dietary and herbal supplement use by multiple sclerosis patients.** *J Neurol* 2012;259:637–44
- Foster M, Zivadinov R, Weinstock-Guttman B, et al. **Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis.** *J Neuroimmunol* 2012;243:61–68
- Jenkinson M, Smith S. **A global optimisation method for robust affine registration of brain images.** *Med Image Anal* 2001;5:143–56
- Zivadinov R, Rudick RA, De Masi R, et al. **Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.** *Neurology* 2001;57:1239–47

30. Polman CH, Reingold SC, Edan G, et al. **Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria."** *Ann Neurol* 2005;58:840–46
31. Benjamini Y, Hochberg Y. **Controlling the false discovery rate: a practical and powerful approach to multiple testing.** *Journal of the Royal Statistical Society Series B (Methodological)* 1995;57:289–300
32. Mehta V, Pei W, Yang G, et al. **Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.** *PLoS One* 2013;8:e57573
33. Eissa A, Lebel RM, Korzan JR, et al. **Detecting lesions in multiple sclerosis at 4.7 Tesla using phase susceptibility-weighting and T2-weighting.** *J Magn Reson Imaging* 2009;30:737–42
34. Rovaris M, Filippi M. **Diffusion tensor MRI in multiple sclerosis.** *J Neuroimaging* 2007;17(suppl 1):27S–30S
35. Richards TL. **Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy.** *AJR Am J Roentgenol* 1991;157:1073–78
36. Tan IL, van Schijndel RA, Pouwels PJ, et al. **MR venography of multiple sclerosis.** *AJNR Am J Neuroradiol* 2000;21:1039–42
37. Tallantyre EC, Morgan PS, Dixon JE, et al. **A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions.** *Invest Radiol* 2009;44:491–94